PubRank

Janet L Stanford

Author PubWeight™ 219.85‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013 7.95
2 Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009 6.04
3 Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004 5.84
4 Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013 5.58
5 Prostate specific antigen best practice statement: 2009 update. J Urol 2009 3.95
6 Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst 2013 3.81
7 Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med 2013 3.74
8 Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003 3.58
9 Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011 3.07
10 Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003 3.07
11 Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 2008 3.05
12 Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005 2.99
13 Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008 2.79
14 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol 2005 2.72
15 Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 2011 2.70
16 Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002 2.54
17 Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002 2.52
18 Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009 2.49
19 Circumcision and the risk of prostate cancer. Cancer 2012 2.48
20 HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet 2012 2.18
21 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol 2008 2.16
22 Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev 2007 2.11
23 Carbonated soft drink consumption and risk of esophageal adenocarcinoma. J Natl Cancer Inst 2006 2.08
24 A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 2005 2.02
25 A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 2005 1.96
26 General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol 2003 1.91
27 Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol 2009 1.88
28 Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. J Urol 2010 1.86
29 Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 2009 1.83
30 A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet 2013 1.82
31 Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet 2013 1.78
32 Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet 2006 1.70
33 Alcohol consumption and risk of prostate cancer in middle-aged men. Int J Cancer 2005 1.69
34 Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev 2010 1.62
35 Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 2005 1.61
36 Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2008 1.58
37 Male pattern baldness and prostate cancer risk in a population-based case-control study. Cancer Epidemiol 2010 1.57
38 Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 2008 1.54
39 Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet 2011 1.54
40 Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev 2011 1.51
41 Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev 2007 1.51
42 Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features. Clin Cancer Res 2009 1.49
43 Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007 1.47
44 A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet 2012 1.47
45 Identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry. PLoS Genet 2011 1.47
46 Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2008 1.42
47 Genetic etiology of hereditary prostate cancer. Front Biosci 2007 1.41
48 Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20-44 years of age. Am J Epidemiol 2002 1.39
49 Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer 2013 1.37
50 Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men. Cancer Causes Control 2007 1.30
51 Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev 2011 1.28
52 Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res 2009 1.27
53 Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res 2009 1.22
54 Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clin Gastroenterol Hepatol 2005 1.21
55 Evaluation of a variant in the transcription factor 7-like 2 (TCF7L2) gene and prostate cancer risk in a population-based study. Prostate 2008 1.21
56 Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. J Urol 2005 1.21
57 Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum Mol Genet 2007 1.20
58 Vitamin D pathway gene variants and prostate cancer prognosis. Prostate 2010 1.20
59 Food group intake and risk of subtypes of esophageal and gastric cancer. Int J Cancer 2008 1.17
60 Semiparametric models of time-dependent predictive values of prognostic biomarkers. Biometrics 2009 1.17
61 Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study. Cancer Causes Control 2009 1.15
62 Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002 1.14
63 Genomic scan of 254 hereditary prostate cancer families. Prostate 2003 1.14
64 C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control 2009 1.13
65 Diabetes mellitus and prostate cancer risk. Prostate 2008 1.12
66 Fine mapping of familial prostate cancer families narrows the interval for a susceptibility locus on chromosome 22q12.3 to 1.36 Mb. Hum Genet 2007 1.10
67 Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer. Clin Cancer Res 2007 1.09
68 Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2011 1.08
69 Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2009 1.07
70 HOXB13 mutations in a population-based, case-control study of prostate cancer. Prostate 2012 1.07
71 Principal component analysis of dietary and lifestyle patterns in relation to risk of subtypes of esophageal and gastric cancer. Ann Epidemiol 2011 1.06
72 Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. Prostate 2013 1.06
73 Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2002 1.04
74 Prostate specific antigen best practice statement: 2009 update. J Urol 2013 1.03
75 Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol 2010 1.02
76 Genetic polymorphisms in inflammation pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2011 1.02
77 Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomarkers Prev 2003 1.02
78 The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening. Prostate 2006 1.01
79 Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. Clin Cancer Res 2011 1.01
80 Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate 2004 1.00
81 Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis. Prostate 2006 0.99
82 Breast implants following mastectomy in women with early-stage breast cancer: prevalence and impact on survival. Breast Cancer Res 2004 0.99
83 Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up. J Gen Intern Med 2008 0.99
84 GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Detect Prev 2007 0.98
85 Multi-institutional prostate cancer study of genetic susceptibility in populations of African descent. Carcinogenesis 2011 0.98
86 Obesity and the risk of prostate cancer. Prostate 2005 0.97
87 Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet 2011 0.97
88 Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk. Prostate 2005 0.97
89 Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer 2014 0.96
90 Racial/Ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. J Clin Oncol 2004 0.95
91 The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate 2011 0.95
92 Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Hum Genet 2015 0.95
93 CYP17 polymorphisms and prostate cancer outcomes. Prostate 2010 0.95
94 Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk. Cancer Epidemiol 2012 0.95
95 Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men. Prostate 2006 0.95
96 Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q. Hum Genet 2007 0.94
97 Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer Epidemiol Biomarkers Prev 2004 0.94
98 Associations of tea and coffee consumption with prostate cancer risk. Cancer Causes Control 2013 0.94
99 Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. J Gen Intern Med 2015 0.94
100 Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Hum Genet 2013 0.93
101 Finding prostate cancer susceptibility genes. Annu Rev Genomics Hum Genet 2004 0.93
102 Vasectomy and the risk of prostate cancer. J Urol 2008 0.93
103 Risk of subsequent breast cancer in relation to characteristics of screening mammograms from women less than 50 years of age. Cancer Epidemiol Biomarkers Prev 2002 0.93
104 Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol 2013 0.91
105 Self-report of prostatitis and its risk factors in a random sample of middle-aged men. Urology 2004 0.91
106 Occupation and risk of esophageal and gastric cardia adenocarcinoma. Am J Ind Med 2002 0.90
107 Dietary intake and risk of postmenopausal breast cancer (United States). Cancer Causes Control 2003 0.90
108 IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate 2005 0.89
109 Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003 0.89
110 Alcohol dehydrogenase 3 and risk of esophageal and gastric adenocarcinomas. Cancer Causes Control 2007 0.89
111 Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. Proc Natl Acad Sci U S A 2004 0.89
112 Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression. Hum Mutat 2012 0.89
113 Germline missense variants in the BTNL2 gene are associated with prostate cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2013 0.89
114 Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes. Cancer Epidemiol Biomarkers Prev 2010 0.89
115 Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses. Prostate 2010 0.88
116 Association between the peroxisome proliferator-activated receptor gamma Pro12Ala variant and haplotype and pancreatic cancer in a high-risk cohort of smokers: a pilot study. Pancreas 2009 0.88
117 Association of hepsin gene variants with prostate cancer risk and prognosis. Prostate 2010 0.88
118 Oligogenic segregation analysis of hereditary prostate cancer pedigrees: evidence for multiple loci affecting age at onset. Int J Cancer 2003 0.87
119 Association of variants in estrogen-related pathway genes with prostate cancer risk. Prostate 2012 0.87
120 Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study. Am J Med 2006 0.87
121 Met160Val polymorphism in the TRMPSS2 gene and risk of prostate cancer in a population-based case-control study. Prostate 2004 0.86
122 Cruciferous vegetables and prostate cancer risk: confounding by PSA screening. Cancer Epidemiol Biomarkers Prev 2004 0.86
123 Some further results on incorporating risk factor information in assessing the dependence between paired failure times arising from case-control family studies: an application to prostate cancer. Stat Med 2002 0.86
124 Association of megalin genetic polymorphisms with prostate cancer risk and prognosis. Clin Cancer Res 2008 0.86
125 Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent. Prostate 2012 0.86
126 Genetic susceptibility to aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2006 0.86
127 Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study. BJU Int 2010 0.86
128 Variation in selenoenzyme genes and prostate cancer risk and survival. Prostate 2012 0.85
129 AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk. Prostate 2010 0.84
130 Statins and the risk of cancer. JAMA 2006 0.84
131 Family-based association analysis of 42 hereditary prostate cancer families identifies the Apolipoprotein L3 region on chromosome 22q12 as a risk locus. Hum Mol Genet 2010 0.83
132 Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men. Cancer Causes Control 2007 0.83
133 Genomic scan of 12 hereditary prostate cancer families having an occurrence of pancreas cancer. Prostate 2007 0.83
134 Genetic variation in RNASEL and risk for prostate cancer in a population-based case-control study. Prostate 2011 0.82
135 Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate 2010 0.82
136 National Cancer Institute Prostate Cancer Genetics Workshop. Cancer Res 2011 0.82
137 Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. Prostate 2011 0.81
138 MSMB gene variant alters the association between prostate cancer and number of sexual partners. Prostate 2013 0.81
139 Is digoxin use for cardiovascular disease associated with risk of prostate cancer? Prostate 2013 0.81
140 Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status. Am J Epidemiol 2015 0.81
141 A study of caloric restriction versus standard diet in overweight men with newly diagnosed prostate cancer: a randomized controlled trial. Prostate 2013 0.79
142 Consumption of deep-fried foods and risk of prostate cancer. Prostate 2013 0.79
143 Coffee and tea consumption in relation to prostate cancer prognosis. Cancer Causes Control 2013 0.79
144 Suggestive genetic linkage to chromosome 11p11.2-q12.2 in hereditary prostate cancer families with primary kidney cancer. Prostate 2007 0.79
145 The monoamine oxidase A gene promoter repeat and prostate cancer risk. Prostate 2012 0.79
146 Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Lett 2008 0.79
147 Genome-wide linkage analyses of hereditary prostate cancer families with colon cancer provide further evidence for a susceptibility locus on 15q11-q14. Eur J Hum Genet 2010 0.79
148 Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. Br J Cancer 2016 0.78
149 Affected relative pairs and simultaneous search for two-locus linkage in the presence of epistasis. Genet Epidemiol 2007 0.76
150 Confirmation of genetic variants associated with lethal prostate cancer in a cohort of men from hereditary prostate cancer families. Int J Cancer 2014 0.76
151 Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families. BMC Med Genet 2012 0.76
152 Searching for epistasis and linkage heterogeneity by correlations of pedigree-specific linkage scores. Genet Epidemiol 2008 0.75
153 Reply to circumcision unlikely to be associated with prostate cancer risk. Cancer 2012 0.75
154 Interest in genetic testing among affected men from hereditary prostate cancer families and their unaffected male relatives. Genet Med 2009 0.75
155 The impact of patents on the development of genome-based clinical diagnostics: an analysis of case studies. Genet Med 2009 0.75
156 The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting. Urol Oncol 2012 0.75